Projects per year
Abstract
The objective of this study was to develop an immediate release dose form containing 250 mg Mefenamic acid (MFA) presented as a crystalline solid dispersion in order to achieve improved consistency in drug release through a simplified formulation compared to a commercial product. An MFA-Soluplus®-Sorbitol polymer matrix was developed using an HME process based on rheological screening assays of physical mixtures. The physico-chemical properties of these formulations were assessed by thermal analysis, FTIR, mechanical testing and SEM image analysis, confirming the crystalline character and stable polymorphic form I of the API in the polymer matrix. A faster release and a significant improvement in consistency (± 6 %) of drug release was observed compared to a commercially available MFA product (± 17 %) (250 mg capsule). This study illustrates advantages of applying a structured development program aimed at retaining API physical properties in the final dosage form.
Original language | English |
---|---|
Journal | Journal of Pharmaceutical Sciences |
Early online date | 25 Aug 2020 |
DOIs | |
Publication status | E-pub ahead of print - 25 Aug 2020 |
Keywords
- extrusion
- solid dosage form
- oral drug delivery
- solid dispersion
- dissolution
- formulation
Fingerprint
Dive into the research topics of 'Improving consistency for a Mefenamic acid immediate release formulation'. Together they form a unique fingerprint.Projects
- 1 Active
Datasets
-
Data for: "Improving consistency for a Mefenamic acid immediate release formulation"
Prasad, E. (Creator), Robertson, J. (Contributor) & Halbert, G. (Supervisor), University of Strathclyde, 19 Aug 2020
DOI: 10.15129/18916640-5b9d-4bea-afed-db2e1ca0f207
Dataset
Research output
- 1 Poster
-
Improving consistency for a Mefenamic acid immediate release formulation
Prasad, E., Robertson, J. & Halbert, G. W., 22 Oct 2020. 1 p.Research output: Contribution to conference › Poster
File